Hidehito Horinouchi, Assistant Chief of the National Cancer Center Hospital, shared a post on X about a recent paper by him and colleagues published in Annals of Oncology:

“Phase 1b study of telisotuzumab vedotin + osimertinib in patients with c-Met overexpressing, EGFR-m NSCLC after progression on prior osi:

MET ADC
ORR 50.0%, mPFS 7.4 mo (95% CI: 5.4, NR) per ICR.”

“Results from a phase 1b study of telisotuzumab vedotin in combination with osimertinib in patients with c-Met protein–overexpressing, EGFR-mutated locally advanced/metastatic non-small cell lung cancer (NSCLC) after progression on prior osimertinib”

Authors: Hidehito Horinouchi et al.

Hidehito Horinouchi: Telisotuzumab Vedotin and Osimertinib in EGFR-Mutated NSCLC

More posts featuring Hidehito Horinouchi.

Hidehito Horinouchi is the Assistant Chief of the National Cancer Center Hospital. He also serves as the Secretary General of the Lung Cancer Study Group, Japan Clinical Oncology Group, and the Deputy Chief of the Center for Education and Professional Career Development at the National Cancer Center Hospital.

He specializes in multimodal treatment strategies, including medical, surgical, and radiation oncology, for patients with thoracic malignancies.